These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27933373)

  • 1. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
    Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
    Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
    Rajan AM; Rajkumar SV
    Semin Oncol; 2016 Dec; 43(6):700-702. PubMed ID: 28061990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
    Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
    Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
    Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
    Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
    Wang TF; Ahluwalia R; Fiala MA; Trinkaus KM; Cox DP; Jaenicke M; Moliske CC; Carson KR; Wildes TM; Tomasson MH; Stockerl-Goldstein KE; Vij R
    Leuk Lymphoma; 2014 Feb; 55(2):337-41. PubMed ID: 23662990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical Considerations in Managing Relapsed Multiple Myeloma.
    Agarwal A; Chow E; Bhutani M; Voorhees PM; Friend R; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):69-77. PubMed ID: 27986429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
    Jimenez-Zepeda VH; Duggan P; Neri P; Tay J; Bahlis NJ
    Ann Hematol; 2017 Mar; 96(3):431-439. PubMed ID: 28074255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
    Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
    Ann Hematol; 2017 Mar; 96(3):441-448. PubMed ID: 27913860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
    Vandross A
    Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.